Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Almirall, Jordi ^a   Bolíbar, Ignasi ^a   Serra Prat, Mateu ^b   Palomera, Elisabet ^b   Roig, Jordi ^c   Hospital, Imma ^d   Carandell, Eugenia ^e   Agustí, Mercè ^d   Ayuso, Pilar ^f   Estela, Andreu ^e   Torres, Antoni ^g  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

^c HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

^d INSTITUT CATALÀ DE LA SALUT   (Spain)

^e Servei Balear de la Salut (IB Salut)   (Spain)

^f INSALUD   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HOME OXYGEN THERAPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTOR;

ADMINISTRATION, INHALATION; ASTHMA; BRONCHITIS, CHRONIC; COMMUNITY-ACQUIRED INFECTIONS; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PNEUMONIA; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STEROIDS; TREATMENT OUTCOME;

EID: 84883528317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073271     Document Type: Article

References (24)

1. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG, (1987) Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1: 671-674. PubMed: 2882091.
2. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, et al. (1993) Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 137: 977-988. PubMed: 8317455.
3. Almirall J, Casado M, Valls F, Morató I, Agudo A, (1991) Estudio prospectivo de las neumonías extrahospitalarias atendidas en un hospital general. Error diagnóstico. Med Clin (Bar) 97: 250-254.
4. Ausina V, Coll P, Sambeat M, Puig I, Condom MJ, et al. (1988) Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 7: 342-347. doi:10.1007/BF01962334. PubMed: 3137033.
5. Oseasohn R, Skipper BE, Tempest B, (1978) Pneumonia in a Navajo community: a two-year experience. Am Rev Respir Dis 117: 1003-1009. PubMed: 666099.
6. Farr BM, Woodhead MA, Macfarlane JT, Bartlett CL, McCraken JS, et al. (2000) Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 94: 422-427. doi:10.1053/rmed.1999.0743. PubMed: 10868703.
7. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789. doi:10.1056/NEJMoa063070. PubMed: 17314337.
8. Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, et al. (2010) Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 36: 1080-1087. doi:10.1183/09031936.00022909. PubMed: 20525710.
9. Kardos P, Wencker M, Glaab T, Vogelmeier C, (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 144-149. doi:10.1164/rccm.200602-244OC. PubMed: 17053207.
10. Ernst P, Gonzalez AV, Brassard P, Suissa S, (2007) Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176: 162-166. doi:10.1164/rccm.200611-1630OC. PubMed: 17400730.
11. Nannini LJ, Cates CJ, Lasserson TJ, Poole P, (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev Volumes 4CD006829.
12. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, et al. (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26. doi:10.1164/rccm.200707-973OC. PubMed: 17916806.
13. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, et al. (2010) Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with chronic obstructive pulmonary disease and hospitalized with pneumonia. Eur Respir J 36: 751-757. doi:10.1183/09031936.00077509. PubMed: 20413535.
14. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, et al. (2009) Pneumonia risk in COPD patient receiving inhaled corticosteroids alone or in combination: TORCH study result. Eur Respir J 34: 641-647.
15. Singanayagam A, Chalmers JD, Hill AT, (2010) Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 103: 379-385. doi:10.1093/qjmed/hcq023. PubMed: 20231237.
16. Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I et al (2008) New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31: 1274-1284 doi:10.1183/09031936.00095807. PubMed: 18216057.
17. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG, (1987) Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1: 671-674. PubMed: 2882091.
18. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, et al. (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377-382. doi:10.1136/thorax.58.5.377. PubMed: 12728155.
19. Initiative Global, for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available: www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. [Accessed: September 19 2008].
20. Grupo, Español del Estudio Europeo del Asma (1995) Prevalencia de síntomas relacionados con el asma in cinco áreas españolas. Med Clin(Barc) 104: 487-492.
21. Sin DD, Lacy P, York E, Man SF, (2004) Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760-765. doi:10.1164/rccm.200404-543OC. PubMed: 15229100.
22. Van Overveld FJ, Demkow UA, Górecka D, Zielinski J, De Backer WA, (2003) Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. Eur J Pharmacol 447: 261-267. PubMed: 14522365.
23. Singh S, Amin AV, Loke YK, (2009) Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169: 219-229. doi:10.1001/archinternmed.2008.550. PubMed: 19204211.
24. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E, (2008) Inhaled corticosteroids in patients with stable chronic-obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 300: 2407-2416. doi:10.1001/jama.2008.717. PubMed: 19033591.